Spanish ‘pharmacy’ to grow profits by 16.4% in 2022, up to 560 million euros

The Spanish pharmaceutical sector returns, again, to gain muscle. Spanish companies listed in the sector In 2022 compared to 2021, they increased their collective net profit by 16.4% to more than 500 million euros. Pharmacy and collected by PlantaDoce.

Grifols, Almiral, Rovi, Rig Joffre, Face Pharma and Pharma Mar have a combined profit of 558.9 million euros in 2022.In the year This increase compared to 480.3 million euros in 2021. In 2021 it will result in a decrease compared to 2020, when the six listed companies will reduce their profits by 51%, due to the poor results of Grifols and the impact of Covid-19.

The most profitable company is Grifols. A specialist in the production of blood products, 2022 closed with a net result of 208 million euros, which represents a growth of 10.4% compared to 2021. Now led by new president Thomas Glanzman, the company has boosted profits thanks to the release of blood plasma.It has grown by more than 25 percent since being hit hard during the pandemic. In particular, the total revenue of the pharmaceutical company focused on the production of blood products improved by 23% compared to 2022, up to 6,064 million euros in 2022, led by major proteins. Biopharma.

Grifols profit in 2010 In 2022 it is twenty million euros higher than in 2021, although it is far from the profit of 618.5 million euros recorded by the Catalan laboratory in 2020.

Behind Grifols is Rovi. The laboratory, which is Moderna’s partner in producing the vaccine against Covid-19, closed in 2022 with a net profit of 199.7 million euros.Compared to 2021, it translates to 30% growth Pharmacy The incentive for the result emphasizes the strength of the business to third parties.

The company’s operating income increased by 26% in 2022, up to 817.7 million euros, thanks to the third-party manufacturing business, which grew by 52% in sales, and the pharmaceutical specialists business, whose sales increased by 8%. The laboratory expects the first quarter of 2023 to include revenue related to vaccine production in the fourth quarter of 2022.And the second quarter of 2023 is the lowest manufacturing sales period for third parties.

Last October, Rovi announced the launch of a plant designed to produce compounds of high biological value Out of the pig’s intestines, which their investment amounts to forty million euros. The facility is located in the Fraga Logistics-Industrial Platform (Aragon). The investment will take place over the next four years and the project is estimated to create around thirty direct jobs.

The third company with the highest profit after Grifols and Rovi is Face Pharma. The pharmaceutical company based in Leoa (Vizcaya) has a profit of 89.5 million euros in 2022.It translates to an 8.6% increase compared to 2021 results.

The pharmaceutical company In 2022, the payment of 462 million euros, an increase of 7.7%, the total operating profit (Ebitda) recorded a 6% increase, up to 121 million euros. Among the company’s recent operations, the acquisition of Novosisys, a pharmaceutical company located in the United Arab Emirates, stands out, which will allow it to strengthen its presence in the region.

Reg Joffrey, on the other hand, made a profit of 8.1 million euros in 2022, which represents an increase of 62% compared to the data in 2021. The company confirmed the recovery of the antibiotics market, while at the same time the new injection plant in Barcelona started industrial production.

of Pharmacy The Catalan company expects revenues of 271 million euros in 2022, more than 15% in 2021, due to the recovery of sales of antibiotics, new production capacity in the new factory, growth in Consumer health care and higher revenues from the new subsidiary in Poland.

Admiral It has a net profit of 4.3 million euros in 2022, compared to a loss of 40.9 million euros in 2021. The normalized net result (including extraordinary items) was 33.5 million euros last year, compared to 81.4 million euros in 2021.

The total revenue of the Spanish pharmaceutical company will reach 866.5 million euros in 2022, which is 6.7% higher than last year. The company highlights the strength of its dermatology business, which grew by more than 14% last year.

Pharma Mar, negative note

Behind Grifols, Rovi and Face Pharma is Pharma Mar. However, it was the only laboratory to reduce its profits last year, from 92.8 million euros in 2021 to 49.3 million euros in 2022.

Pharma Mar’s decline is mainly due to non-recurring revenue recorded in 2021.As stated by the Spanish pharmaceutical company. Also, to a lesser extent, changes in regulations in France regulate the price of medicines available through the compassionate access licensing system. 92% of the company’s total revenue is generated outside of Spain.

On September 27, 2022, PharmaMar decided to cease activity in the investigational area.Developed by 100% owned Genomica. As a result, it was agreed to initiate the liquidation and liquidation of this company.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top